688131.SH
皓元医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 91.66
−5.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.0B | 2.9B | 2.3B | 1.9B | 1.4B |
| Cost of Revenue | 1.6B | 1.5B | 1.2B | 1.0B | 659.4M |
| Gross Profit | 1.4B | 1.4B | 1.1B | 849.2M | 698.6M |
| Operating Expenses | |||||
| R&D Expense | 248.4M | 237.6M | 226.9M | 224.1M | 201.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 348.6M | 323.9M | 235.0M | 220.2M | 169.0M |
| Selling & Marketing Expense | 305.4M | 278.2M | 209.9M | 158.0M | 110.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.0B | 920.7M | 719.6M | 641.8M | 485.3M |
| Cost and Expenses | 2.6B | 2.4B | 1.9B | 1.7B | 1.1B |
| Operating Income (EBIT) | 296.0M | 296.8M | 236.8M | 128.3M | 196.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 276.7M | 275.8M | 238.4M | 128.2M | 198.5M |
| Income Tax Expense | 43.2M | 44.1M | 40.4M | 1.9M | 7.0M |
| Bottom Line | |||||
| Net Income | 245.3M | 239.8M | 201.6M | 127.4M | 193.6M |
| Earnings from Cont. Ops | 233.5M | 231.6M | 197.9M | 126.3M | 191.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 245.3M | 239.8M | 201.6M | 127.4M | 193.6M |
| Per Share | |||||
| Basic EPS | CN¥1.16 | CN¥1.13 | CN¥0.96 | CN¥0.61 | CN¥1.33 |
| Diluted EPS | CN¥1.16 | CN¥1.13 | CN¥0.96 | CN¥0.61 | CN¥1.33 |
| Revenue Per Share | CN¥14.15 | CN¥13.56 | CN¥10.81 | CN¥9.00 | CN¥9.33 |
| Shares | |||||
| Basic Shares Outstanding | 212.0M | 212.2M | 210.0M | 208.9M | 145.6M |
| Diluted Shares Outstanding | 212.0M | 212.2M | 210.0M | 208.9M | 145.6M |
| Profitability Metrics | |||||
| EBITDA | — | 453.1M | 384.9M | 246.1M | 255.6M |
| D&A | — | 156.3M | 148.1M | 117.7M | 59.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026